Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Ipsen, Spirogen deal

Ipsen (formerly Beaufour Ipsen), acquired global rights to develop the preclinical antitumor agent

Read the full 137 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE